newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Ongoing progress toward last patient enrolled in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2